US 7,405,051 B2 · Method of screening antiplatelet agents

Abstract

A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.

A method of screening for an agent that inhibits platelet aggregation, comprising the steps of:

detecting whether or not a compound is an ADP receptor P2TAC ligand, antagonist, or agonist by at least one method selected from
(a) a method for detecting whether or not the compound is an ADP receptor p2TAC ligand, comprising the steps of:
bringing a transformant cell membrane fraction comprising at least one of
(1) a polypeptide comprising the amino acid sequence of SEQ ID NO:
2;
(2) a polypeptide comprising an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, and/or added in the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi;
or
(3) a polypeptide comprising an amino acid sequence having a 95% or more homology with the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi, or
bringing a transformant which is transformed with an expression vector comprising a DNA encoding at least one of said polypeptides (1) to (3),
into contact with the compound, in the presence of a labeled ligand of an ADP receptor P2TAC;and
analyzing the amount of the labeled ligand which binds to the transformant cell membrane fraction or the transformant in the presence of and in the absence of the compound,
wherein the ADP receptor P2TAC ligand is identified when the amount of labeled ligand that binds to the transformant cell membrane fraction or the transformant is lower in the presence of the compound than in the absence of the compound;
(b) a method for detecting whether or not the compound is an ADP receptor P2TAC antagonist or agonist, comprising the steps of:
bringing the compound and optionally a known ADP receptor P2TAC agonist into contact with a transformant which is transformed with an expression vector comprising a DNA encoding
(1) a polypeptide comprising the amino acid sequence of SEQ ID NO:
2;
(2) a polypeptide comprising an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, and/or added in the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi;
or
(3) a polypeptide comprising an amino acid sequence having a 95% or more homology with the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi
said transformant co-expressing a G protein chimera comprising a polypeptide having an activity of promoting a phospholipase C activation, said G protein chimera having the amino acid sequence of SEQ ID NO:
11 at the C-terminus;
and
analyzing the intracellular Ca2+ concentration in the transformant in the presence of and in the absence of the compound, wherein if the intracellular Ca2+ increases in the presence of the compound and does not increase in the presence of the compound in a cell that does not express the polypeptide described in (1), (2) or (3), the compound is an ADP receptor p2TAC agonist and wherein if the intracellular Ca2+ decreases in the presence of the compound and the known ADP receptor p2TAC agonist, the compound is an ADP receptor p2TAC antagonist;
and
(c) a method for detecting whether or not the compound is an ADP receptor p2TAC antagonist or agonist, comprising the steps of:
bringing a transformant which is transformed with an expression vector comprising a DNA encoding
(1) a polypeptide comprising the amino acid sequence of SEQ ID NO:
2;
(2) a polypeptide comprising an amino acid sequence in which 1 to 10 amino acids are deleted, substituted, and/or added in the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi;
or
(3) a polypeptide comprising an amino acid sequence having a 95% or more homology with the amino acid sequence of SEQ ID NO:
2, and exhibiting an activity of suppressing an adenylate cyclase activity by binding to ADP and coupling with Gi
into contact with the compound and optionally a known ADP receptor p2TAC agonist;
and
analyzing the intracellular cAMP concentration in the transformant in the presence of and in the absence of the compound, wherein if the intracellular cAMP decreases in the presence of the compound and does not decrease in the presence of the compound in a cell that does not express the polypeptide described in (1), (2) or (3), the compound is an ADP receptor P2TAC agonist and wherein if the intracellular cAMP does not decrease in the presence of the compound and the known ADP receptor p2TAC agonist, the compound is an ADP receptor p2TAC antagonist;
selecting the ADP receptor p2TAC antagonist as the agent;
and
confirming that the selected ADP receptor p2TAC antagonist exhibits a platelet aggregation inhibition activity by detecting inhibition of human platelet aggregation by the selected ADP receptor p2TAC antagonist.

40 more elements

Method of screening antiplatelet agents

Life of this patent

Method of screening antiplatelet agents

Life of this patent

Abstract

Claims2